Biofilm formation – what we can learn from recent developments
Research output: Contribution to journal › Review › Research › peer-review
Standard
Biofilm formation – what we can learn from recent developments. / Bjarnsholt, T.; Buhlin, K.; Dufrêne, Y. F.; Gomelsky, M.; Moroni, A.; Ramstedt, M.; Rumbaugh, K. P.; Schulte, T.; Sun, L.; Åkerlund, B.; Römling, U.
In: Journal of Internal Medicine, Vol. 284, No. 4, 2018, p. 332-345.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Biofilm formation – what we can learn from recent developments
AU - Bjarnsholt, T.
AU - Buhlin, K.
AU - Dufrêne, Y. F.
AU - Gomelsky, M.
AU - Moroni, A.
AU - Ramstedt, M.
AU - Rumbaugh, K. P.
AU - Schulte, T.
AU - Sun, L.
AU - Åkerlund, B.
AU - Römling, U.
PY - 2018
Y1 - 2018
N2 - Although biofilms have been observed early in the history of microbial research, their impact has only recently been fully recognized. Biofilm infections, which contribute to up to 80% of human microbial infections, are associated with common human disorders, such as diabetes mellitus and poor dental hygiene, but also with medical implants. The associated chronic infections such as wound infections, dental caries and periodontitis significantly enhance morbidity, affect quality of life and can aid development of follow-up diseases such as cancer. Biofilm infections remain challenging to treat and antibiotic monotherapy is often insufficient, although some rediscovered traditional compounds have shown surprising efficiency. Innovative anti-biofilm strategies include application of anti-biofilm small molecules, intrinsic or external stimulation of production of reactive molecules, utilization of materials with antimicrobial properties and dispersion of biofilms by digestion of the extracellular matrix, also in combination with physical biofilm breakdown. Although basic principles of biofilm formation have been deciphered, the molecular understanding of the formation and structural organization of various types of biofilms has just begun to emerge. Basic studies of biofilm physiology have also resulted in an unexpected discovery of cyclic dinucleotide second messengers that are involved in interkingdom crosstalk via specific mammalian receptors. These findings even open up new venues for exploring novel anti-biofilm strategies.
AB - Although biofilms have been observed early in the history of microbial research, their impact has only recently been fully recognized. Biofilm infections, which contribute to up to 80% of human microbial infections, are associated with common human disorders, such as diabetes mellitus and poor dental hygiene, but also with medical implants. The associated chronic infections such as wound infections, dental caries and periodontitis significantly enhance morbidity, affect quality of life and can aid development of follow-up diseases such as cancer. Biofilm infections remain challenging to treat and antibiotic monotherapy is often insufficient, although some rediscovered traditional compounds have shown surprising efficiency. Innovative anti-biofilm strategies include application of anti-biofilm small molecules, intrinsic or external stimulation of production of reactive molecules, utilization of materials with antimicrobial properties and dispersion of biofilms by digestion of the extracellular matrix, also in combination with physical biofilm breakdown. Although basic principles of biofilm formation have been deciphered, the molecular understanding of the formation and structural organization of various types of biofilms has just begun to emerge. Basic studies of biofilm physiology have also resulted in an unexpected discovery of cyclic dinucleotide second messengers that are involved in interkingdom crosstalk via specific mammalian receptors. These findings even open up new venues for exploring novel anti-biofilm strategies.
KW - antimicrobial strategies
KW - biofilm formation
KW - cyclic di-nucleotide second messengers
KW - extracellular matrix
KW - underlying diseases
U2 - 10.1111/joim.12782
DO - 10.1111/joim.12782
M3 - Review
C2 - 29856510
AN - SCOPUS:85050493569
VL - 284
SP - 332
EP - 345
JO - Journal of Internal Medicine
JF - Journal of Internal Medicine
SN - 0955-7873
IS - 4
ER -
ID: 203871688